Analysis of patient adherence to treatment by DOAC I

Analysis of patient adherence to treatment by DOAC I Author: Katarína Rezáková Tutor: doc. PharmDr. Josef Malý, Ph.D. Consultant: PharmDr. Kateřina Malá, Ph.D. Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Králové, Charles University Introduction and aims: Atrial fibrillation (AF) is the most common supraventricular tachyarrhythmia associated with increased morbidity and mortality. In clinical practice, direct oral anticoagulants (DOAC) are used as an alternative to warfarin to prevent thromboembolic events in patients with AF. The study aimed to analyse the statements of patients with FiP along with data from medical records focusing on aspects related to the use and management of DOAC, including devices and tools to improve adherence to treatment, patients' level of awareness of DOAC and other therapeutic agents used. Methods: The prospective study was conducted from 2020 to 2022 at the University Hospital Brno. Patients aged ≥ 18 years with AF on DOAC therapy (dabigatran, rivaroxaban and apixaban) were included in the study. Data about pharmacotherapy and patients' health status were obtained from medical records and structured interview with the patient. Patients' interviews were performed at time 0, three and six months after patient has entred the study...